Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study
Mutchnick MG, Lindsay KL, Schiff ER, et al. Journal of Viral Hepatitis 1999;6:397-403.
What it found
Complete response was seen in 14% on thymosin alpha-1 and 4% on placebo (P = 0.084), and sustained loss of HBV DNA with negative HBeAg in 25% versus 13% (P < 0.11). The authors concluded the results did not confirm earlier reports of benefit.
Limitations
Fewer than 100 patients, so modest differences could be missed. HBeAg-positive patients only.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.